Search for Terms or Answers
Researchers at University of California San Diego School and the Icahn School of Medicine have found a high-resolution epigenomic landscape of rheumatoid arthritis (RA) that overlaps with that seen in Huntington's disease, suggesting potentially new unanticipated pathways that could be devel
A study from the Netherlands has shown that the long-term drug survival of TNF inhibitors differ between men and women, with women having a lower long-term retention rate compared to men. A single-center, retrospective study of 122 anklylosing spondylitis (AS) patients, analyzed the outcomes of those receiving either etanercept, adalimumab, or infliximab between 2004 and 2014.
Nearly 40% were women and most AS patients received adalimumab (59.7%), compared to etanercept (28.9%) or infliximab (11.3%).
A population based study from southern Denmark finds excess mortality RF-positive males with rheumatoid arthritis (RA) and that employment status and comorbidity were independent predictors of mortality.
Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans.
Dr. Jack Cush reviews highlights, news and journal articles from the past week on RheumNow.com.
The European League Against Rheumatism (EULAR) convened a multidisciplinary task force including health professionals and patient representatives to develop evidence-based recommendations for pain management in patients with inflammatory arthritis (IA) and osteoarthritis (OA).
Geriatric patients are at a higher risk for obstructive sleep apnea (OSA), yet they are seldom diiagnosed or evaluated for OSA.
A recent study shows that 56% of people 65 years and older have a high risk of OSA, but that only 8% were tested for OSA.
Patients with rheumatoid arthritis (RA) who had previously had an inadequate response to one biologic agent remained on tocilizumab (Actemra) longer than on a tumor necrosis factor (TNF) inhibitor, whether or not conventional disease modifying anti-rheumatic drugs (DMARDs) were given concomitantl
A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics.
Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.
Acthar is in the news again. Previously a New York Times article lambasted the drug as the "single most expensive drug per patient", based on it costing Medicare $16,2371 per patient for nearly 3100 patients. Overall, costing Medicare a half-billion US dollars per year.
A retrospective follow-up study of 499 lupus nephritis (LN) patients over three successive eras shows that LN has become less severe in recent years and thus, better long-term survival is possible.
Mortality remains high in granulomatosis with polyangiitis (GPA), but the causes of death tend to change over time, a researcher reported here.
The CDC's May 4th MMWR reports that from 2002 to 2014, the prevalence of health care provider counseling for weight loss among adults with arthritis and overweight or obesity increased by 10% (from 35% to 45%).
Among the 54.4 million adults with doctor-diagnosed arthritis in the United States, 32.7% are overweight and 38.1% are obese. Moreover obesity is more prevalent among persons with arthritis than among those who do not have arthritis.
A report in Endocrine Practice shows that drug holidays from bisphosphonates results in a 15% risk of fractures. (Citation source:
Dr. Jack Cush discusses the news and journal articles from the past week on RheumNow.com.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
